The most recently added clinical trials across every neurology subspecialty — one feed, updated continuously. Get them weekly by email or via RSS.
Primary: mRS 0-1 at 90 days in 57.5% (123/214) with adjunctive IA alteplase vs 42.5% (93/219) with thrombectomy alone — adjusted risk difference 15.0% (95% CI, 5.7-24.3); P=.002. Ordinal shift analysis of 90-day mRS: no…
View trial →Tenecteplase (0.25 mg/kg) achieved a 2.9-fold higher rate of substantial reperfusion on initial angiogram vs low-dose alteplase (10.3% vs 3.6%; absolute difference 6.5 pp, 90% CI 0.89–12.1), meeting the prespecified succ…
View trial →Primary 1-year endpoint: mean utility-weighted mRS was higher (better) with IAT vs MM (3.65 [SD 0.22] vs 2.78 [SD 0.17]; bayesian adjusted mean difference 1.18, 95% CrI 0.42-1.93; posterior probability of superiority 0.9…
View trial →No dose-limiting toxic effects; mild-to-moderate infusion-related reactions and transient ALT elevations observed Dose-dependent mean PCSK9 reductions: 51% at 0.3 mg/kg to 88% at 1.0 mg/kg Dose-dependent mean LDL cholest…
View trial →Primary outcome (mean AAT language score) improved significantly more with ILAT than with matched-intensity conventional SLT: significant Time × Therapy Type interaction F(1,42)=7.42, p=0.009, η²p=0.15 Within-group: ILAT…
View trial →Good functional status (mRS 0-3) at 90 days: 46% thrombectomy vs 23% control (adjusted rate ratio 2.06, 95% CI 1.46-2.91, P
View trial →Alemtuzumab 12 mg reduced relapse rate by 49.4% vs interferon beta 1a (35% vs 51% relapsed; rate ratio 0.51 [95% CI 0.39-0.65] from recurrent-event proportional means model; p
View trial →Alemtuzumab reduced the risk of sustained accumulation of disability by 71% vs interferon beta-1a (9.0% vs 26.2%; HR 0.29; 95% CI 0.16-0.54; P
View trial →Persistent high-level EBNA-1 peptide antibody titers (>=2 of 4 samples) were present in 96.2% of MS patients vs 7.7% MOGAD (OR 303.4, 95% CI 94.4-908.6) and 18.0% NMOSD (OR 114.9, 95% CI 43.0-280.0) in the test cohort Am…
View trial →Phase 2b, randomized 1:1, double-blind, placebo-controlled; 57 levodopa-naïve early-PD patients; bezisterim 20 mg BID vs placebo × 12 weeks. PRIMARY endpoint was PHARMACODYNAMIC (hematologic inflammatory indices — NLR, M…
View trial →Primary endpoint NOT met: no significant between-group difference in MDS-UPDRS III OFF at 12 months (DiD 1.5, 95% CI -1.5 to 4.4, adjusted p=1.00) MDS-UPDRS III ON was significantly better in the FMT arm at 1 month (DiD…
View trial →First positive phase 3 RCT in ataxia-telangiectasia: levacetylleucine reduced SARA total score by −1·92 vs −0·14 with placebo (linear mixed model treatment effect −1·88, 95% CI −2·70 to −1·06; p
View trial →Vemircopan did NOT meet primary endpoint: ≥2-point MG-ADL reduction for 4 consecutive weeks achieved in 57% (180 mg) and 57% (120 mg) vs 64% placebo (differences −7.1%, P=.68 and P=.73) No significant differences on any…
View trial →Systematic review and meta-analysis of 4 studies (2 RCTs: EMBARK, Study 102; 2 non-randomized: ENDEAVOR, Study 101) with 302 boys aged 4–
View trial →FcRn inhibitors, C5 complement inhibitors (C5i), and CD19+ B-cell depletion therapy (BCDT) showed comparable efficacy — differences between active classes did not meet minimum clinically important thresholds (QMG 3 pts;…
View trial →No intervention group differences in longitudinal cognitive or imaging outcomes (global Aβ, ERC tau, HC volume, WMH volume) Intervention group differences were not associated with or moderated by Aβ status or accumulatio…
View trial →* ABBV-916 significantly reduced brain amyloid at 24 weeks, with greater reductions at higher doses. * Amyloid negativity was achieved in 55% (300 mg), 100% (900 mg), and 71% (2000→900 mg). * ARIA-E occurred in 34% and A…
View trial →Oral semaglutide 14 mg did NOT slow decline on CDR-SB at week 104: estimated difference vs placebo −0·08 (95% CI −0·35 to 0·20; p=0·57) in evoke and 0·10 (−0·17 to 0·38; p=0·46) in evoke+. ADCS-ADL-MCI at week 104 showed…
View trial →Primary — treatment discontinuation due to TEAEs across 24 weeks: 12% (33/273) atogepant vs 30% (79/267) topiramate; RR 0·4 (95% CI 0·3–0·6), p
View trial →Responder rates (≥50% reduction in monthly migraine days/attacks at weeks 9-12): rivaroxaban 78.4% (185/236), clopidogrel 66.8% (157/235), aspirin 61.7% (148/240), metoprolol 61.8% (144/233) All three antithrombotics wer…
View trial →No difference in 48-h relapse: dexamethasone 39% (16/41) vs placebo 44% (20/46); risk difference −4% (95% CI −32% to 24%). No difference in median pain (VAS or VNS) at 48 h or 7 days, return to school, return to normal a…
View trial →HCT-ASCT nearly halved the risk of progression or death vs R-DeVIC (HR 0.43, 95% CI 0.27-0.68; p=0.0003) 3-year progression-free survival 78% (HCT-ASCT) vs 51% (R-DeVIC); 3-year overall survival 86% vs 71% (HR 0.46, p=0.…
View trial →Primary endpoint NOT met: median OS not improved over historical control in any arm (trial OS 11.1 mo vs historical 10.8 mo); trial stopped for futility. Pairwise comparisons all non-significant: everolimus vs dasatinib…
View trial →Single oHSV injection induced deep, persistent T cell infiltration into GBM up to >2 years post-treatment (median T cell density 30.4 pre vs 138 cells/mm² post by Xenium, p=0.0078) CD8/Treg ratio rose from 6.8 pre to 21.…
View trial →Primary safety endpoint met: SADE rate 6.9% (6/87) at 84 days, well below 25% performance goal (p90% of patients and 86% of physicians reported improvement on Global Impression of Change scales No adverse effects on cogn…
View trial →Bayley-III cognitive composite scores at 24 months were similar between early vigabatrin and placebo groups (no significant difference) No significant differences in overall epilepsy incidence, drug-resistant epilepsy at…
View trial →